Welcome to AMYPAD!
We are a collaborative research initiative aiming to improve the understanding, diagnosis and management of Alzheimer’s disease through the utilisation of ß-amyloid PET imaging.
The Amyloid imaging to prevent Alzheimer’s disease (AMYPAD) initiative aims to:
Neuraceq™ (left) and Vizamyl™ (right). Upper images: amyloid negative scans. Lower images: amyloid positive scans.
Latest News
Interview with Isadora Lopes Alves
28 Aug 2017
As a postdoctoral researcher working at the VUmc team, I have two main roles in AMYPAD......
Interview with Nicola Raffa
28 Aug 2017
I share the leadership of the WP3 with Giovanni Frisoni and I attend, on behalf of Andrew Stephens, the Chief Medical Officer of Piramal......
Better understanding risk and disease progression through collaboration
28 Aug 2017
Over the past months, WP5 has been in contact with several research groups in order to establish collaborations......
"At this moment, there is a massive effort to better understand the natural history of Alzheimer’s Disease (AD), as well to improve its management. These efforts wish to increase the chances of success for future clinical trials by allowing them to target populations at the early stages of the disease, when the damage could still be reversed. AMYPAD comes to provide valuable insight on a fundamental piece of the AD puzzle: the accumulation of β-amyloid plaques. We will be doing so by determining the role and value of amyloid imaging in disease diagnosis, prognosis, and potential for treatment monitoring - which will be a crucial step forward in the global fight against AD.” Frederik Barkhof
AMYPAD Project Coordinator and Professor of Neuroradiology at VU University Medical Centre, Amsterdam and at University College London.
